Cochrane Evidence Synthesis and Methods ►

Oral etoposide for treatment and/or maintenance treatment of recurrent epithelial ovarian cancer

To assess the clinical therapeutic efficacy and adverse effects of oral etoposide as treatment and/or maintenance treatment in women with recurrent epithelial ovarian cancer.

This is a protocol.

Health topics:

Cancer > Gynaecological > Ovary

Gynaecology > Cancer > Ovary

Published:

17 February 2020

Authors:

Okunade K, Akinsete AM, Salako O, Afolabi B, Neal RD

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Okunade K, Akinsete AM, Salako O, Afolabi B, Neal RD. Oral etoposide for treatment and/or maintenance treatment of recurrent epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2020, Issue 2. Art. No.: CD013537. DOI: 10.1002/14651858.CD013537